Abstract
Background: 68Ga-PSMA is a widely useful PET/CT tracer for prostate cancer imaging. Being a transmembrane protein acting as a glutamate carboxypeptidase enzyme, PSMA is highly expressed in prostate cancer cells. PSMA can also be labeled with 64Cu, offering a longer half-life and different resolution imaging. Several studies documented bio-distribution and pitfalls of 68Ga-PSMA as well as of 64Cu- PSMA. No data are reported on differences between these two variants of PSMA. Our aim was to evaluate physiological distribution of these two tracers and to analyze false positive cases.
Methods: We examined tracer bio-distribution in prostate cancer patients with negative 68Ga-PSMA PET/CT (n=20) and negative 64Ga-PSMA PET/CT (n=10). A diagnostic pitfall for each tracer was documented.
Result: Bio-distribution of both tracers was similar, with some differences due to renal excretion of 68Ga- PSMA and biliary excretion of 64Cu-PSMA. 68Ga-PSMA uptake was observed in sarcoidosis while 64Cu- PSMA uptake was recorded in pneumonitis.
Discussion: Both tracers may present similar bio-distribution in the human body, with similar uptake in exocrine glands and high intestinal uptake. Similarly to other tracers, false positive cases cannot be excluded in clinical practice.
Conclusion: The knowledge of difference in bio-distribution between two tracers may help in interpretation of PET data. Diagnostic pitfalls can be documented, due to the possibility of PSMA uptake in inflammation. Our results are preliminary to future studies comparing diagnostic accuracies of 68Ga-PSMA and 64Cu-PSMA.
Keywords: 64Cu-PSMA, 68Ga-PSMA, PET/CT, distribution, pitfalls, prostate cancer.
Graphical Abstract
[1]
Banerjee, S.R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Green, G.; Fox, J.J.; Horti, A.; Mease, R.C.; Pomper, M.G. 68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J. Med. Chem., 2010, 22, 5333-5341.
[2]
Afshar-Oromieh, A.; Malcher, A.; Eder, M.; Eisenhut, M.; Linhart, H.G.; Hadaschik, B.A. Holland-Letz, T.; Giesel, F.L.; Kratochwil, C.; Haufe, S.; Haberkorn, U.; Zechmann, CM. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging, 2013, 40, 486-495.
[3]
Sanli, Y.; Kuyumcu, S.; Sanli, O.; Buyukkaya, F.; İribaş, A.; Alcin, G.; Darendeliler, E.; Ozluk, Y.; Yildiz, S.O.; Turkmen, C. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Ann. Nucl. Med., 2017, 31, 709-717.
[4]
Verburg, F.A.; Pfister, D.; Drude, N.I.; Mottaghy, F.M.; Behrendt, F.F. PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer. Nuklearmedizin, 2017, 18, 225-232.
[5]
Bluemel, C.; Krebs, M.; Polat, B.; Linke, F.; Eiber, M.; Samnick, S.; Lapa, C.; Lassmann, M.; Riedmiller, H.; Czernin, J.; Rubello, D.; Bley, T.; Kropf, S.; Wester, H.J.; Buck, A.K.; Herrmann, K. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT. Clin. Nucl. Med., 2016, 41, 515-521.
[6]
Afshar-Oromieh, A.; Haberkorn, U.; Eder, M.; Eisenhut, M.; Zechmann, C.M. [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 1085-1086.
[7]
Kratochwil, C.; Giesel, F.L.; Eder, M.; Afshar-Oromieh, A.; Benesova, M.; Mier, W.; Kopka, K.; Haberkorn, U. [177Lu] Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42, 987-988.
[8]
Singh, A.; Kulkarni, H.R.; Baum, R.P. Imaging of prostate cancer using 64Cu-Labeled Prostate-specific membrane antigen ligand. PET Clin., 2017, 12, 193-203.
[9]
Cantiello, F.; Gangemi, V.; Cascini, G.L.; Calabria, F.; Moschini, M.; Ferro, M.; Musi, G.; Butticè, S.; Salonia, A.; Briganti, A.; Damiano, R. Diagnostic Accuracy of 64Copper prostate-specific membrane antigen positron emission tomography/computed tomography for primary lymph node staging of intermediate- to high-risk prostate cancer: our preliminary experience. Urology, 2017, 106, 139-145.
[10]
Umbricht, C.A.; Benešová, M.; Schmid, R.M.; Türler, A.; Schibli, R.; van der Meulen, N.P.; Müller, C. 44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617-preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617. EJNMMI Res., 2017, 7, 9.
[11]
Strele-Trieb, P.; Dunzinger, A.; Sonnberger, M.; Wolfsgruber, J.; Pichler, R. Uptake of 68Ga-Prostate-specific membrane antigen pet in adrenal gland: a potential pitfall. Clin. Nucl. Med., 2017, 43, 50-51.
[12]
Jochumsen, M.R.; Dias, A.H.; Bouchelouche, K. Benign traumatic rib fracture: a potential pitfall on 68Ga-prostate-specific membrane Antigen PET/CT for Prostate Cancer. Clin. Nucl. Med., 2018, 43, 38-40.
[13]
Gykiere, P.; Goethals, L.; Everaert, H. Healing sacral fracture masquerading as metastatic bone disease on a 68Ga-PSMA PET/CT. Clin. Nucl. Med., 2016, 41, e346-e347.
[14]
Elri, T.; Aras, M.; Salihoglu, Y.S.; Erdemir, R.U.; Cabuk, M. A potential pitfall in the use of 68Ga-PSMA PET/CT: anthracosis. Rev. Esp. Med. Nucl. Imagen Mol., 2017, 36, 65-66.
[15]
Kanthan, G.L.; Drummond, J.; Schembri, G.P.; Izard, M.A.; Hsiao, E. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin. Nucl. Med., 2016, 41, 331-332.
[16]
Calabria, F.; Gangemi, V.; Gullà, D.; Schillaci, O.; Cascini, G.L. 64Cu-PSMA uptake in meningioma: a potential pitfall of a promising radiotracer. Rev. Esp. Med. Nucl. Imagen Mol., 2017, 36, 335-336.
[17]
Silver, D.A.; Pellicer, I.; Fair, W.R.; Heston, W.D.; Cordon-cardo, C. Prostate specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res., 1997, 3, 81-85.
[18]
Shreve, P.D.; Anzai, Y.; Wahl, R.L. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics, 1999, 19, 61-77.
[19]
Kostakoglu, L.; Hardoff, R.; Mirtcheva, R.; Goldsmith, S.J. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake. Radiographics, 2004, 24, 1411-1431.
[20]
Corrigan, A.J.; Schleyer, P.J.; Cook, G.J. Pitfalls and artifacts in the use of PET/CT in oncology imaging. Semin. Nucl. Med., 2015, 45, 481-499.
[21]
Flukes, S.; Lenzo, N.; Moschilla, G.; Sader, C. Positron emission tomography-positive thyroid nodules: rate of malignancy and histological features. ANZ J. Surg., 2016, 86, 487-491.
[22]
Cook, G.J.; Maisey, M.N.; Fogelman, I. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur. J. Nucl. Med., 1999, 26, 1363-1378.
[23]
Calabria, F.F.; Chiaravalloti, A.; Jaffrain-Rea, M.L.; Zinzi, M.; Sannino, P.; Minniti, G.; Rubello, D.; Schillaci, O. 18F-DOPA PET/CT physiological distribution and pitfalls: experience in 215 patients. Clin. Nucl. Med., 2016, 41, 753-760.
[24]
Calabria, F.; Chiaravalloti, A.; Cicciò, C.; Gangemi, V.; Gullà, D.; Rocca, F.; Gallo, G.; Cascini, G.L.; Scillacio, O. PET/CT with 18F-choline: Physiological whole bio-distribution in male and female subjects and diagnostic pitfalls on 1000 prostate cancer patients: 18F-choline PET/CT bio-distribution and pitfalls. A southern Italian experience. Nucl. Med. Biol., 2017, 51, 40-54.
[25]
Calabria, F.; Gallo, G.; Schillaci, O.; Cascini, G.L. Bio-distribution, imaging protocols and diagnostic accuracy of pet with tracers of lipogenesis in imaging prostate cancer: a comparison between 11C-choline, 18Ffluoroethylcholine and 18F-methylcholine. Curr. Pharm. Des., 2015, 21, 4738-4747.
[26]
Beheshti, M.; Haroon, A.; Bomanji, J.B.; Langsteger, W. Fluorocholine PET/computed tomography: physiologic uptake, benign findings, and pitfalls. PET Clin., 2014, 9, 299-306.
[27]
Welle, C.L.; Cullen, E.L.; Peller, P.J.; Lowe, V.J.; Murphy, R.C.; Johnson, G.B.; Binkovitz, L.A. 11C-choline PET/CT in recurrent prostate cancer and nonprostatic neoplastic processes. Radiographics, 2016, 36, 279-292.
[28]
Kirchner, J.; Schaarschmidt, B.M.; Sawicki, L.M.; Heusch, P.; Hautzel, H.; Ermert, J.; Rabenalt, R.; Antoch, G.; Buchbender, C. Evaluation of practical interpretation hurdles in 68Ga-PSMA PET/CT in 55 patients: physiological tracer distribution and incidental tracer uptake. Clin. Nucl. Med., 2017, 42, e322-e327.
[29]
Vellani, C.; Hodolič, M.; Chytiris, S.; Trifirò, G.; Rubello, D.; Colletti, P.M. Early and delayed 18F-FCH PET/CT imaging in parathyroid adenomas. Clin. Nucl. Med., 2017, 42, 143-144.
[30]
Afshar-Oromieh, A.; Wolf, M.B.; Kratochwil, C.; Giesel, F.L.; Combs, S.E.; Dimitrakopoulou-Strauss, A.; Gnirs, R.; Roethke, M.C.; Schlemmer, H.P.; Haberkorn, U. Comparison of 68Ga-DOTATOC-PET/CT and PET/MRI hybrid systems in patients with cranial meningioma: initial results. Neuro-oncol., 2015, 17, 312-319.
[31]
Gerster-Gilliéron, K.; Forrer, F.; Maecke, H.; Mueller-Brand, J.; Merlo, A.; Cordier, D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J. Nucl. Med., 2015, 56, 1748-1751.
[32]
Pfob, C.H.; Ziegler, S.; Graner, F.P.; Köhner, M.; Schachoff, S.; Blechert, B.; Wester, H.J.; Scheidhauer, K.; Schwaiger, M.; Maurer, T.; Eiber, M. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43, 1962-1970.
[33]
Grubmüller, B.; Baum, R.P.; Capasso, E.; Singh, A.; Ahmadi, Y.; Knoll, P.; Floth, A.; Righi, S.; Zandieh, S.; Meleddu, C.; Shariat, S.F.; Klingler, H.C.; Mirzaei, S. 64Cu-PSMA-617 PET/CT imaging of prostate adenocarcinoma: first in-human studies. Cancer Biother. Radiopharm., 2016, 31, 277-286.
[34]
Prasad, V.; Steffen, I.G.; Diederichs, G.; Makowski, M.R.; Wust, P.; Brenner, W. Biodistribution of [(68)Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol. Imaging Biol., 2016, 18, 428-436.
[35]
Demirci, E.; Sahin, O.E.; Ocak, M.; Akovali, B.; Nematyazar, J.; Kabasakal, L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging. Nucl. Med. Commun., 2016, 37, 1169-1179.
[36]
Thomas, L.; Balmus, C.; Ahmadzadehfar, H.; Essler, M.; Strunk, H.; Bundschuh, R.A. Assessment of bone metastases in patients
with prostate cancer-a comparison between 99mTc-Bonescintigraphy
and 68Ga-PSMA PET/CT. Pharmaceuticals(Basel), 2017, 31, 10(3), pii: E68.
[37]
Blazak, J.K.; Thomas, P. Paget disease: a potential pitfall in psma pet for prostate cancer. Clin. Nucl. Med., 2016, 41, 699-700.
[38]
Schillaci, O.; Calabria, F.; Tavolozza, M.; Cicciò, C.; Carlani, M.; Caracciolo, C.R.; Danieli, R.; Orlacchio, A.; Simonetti, G. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl. Med. Commun., 2010, 31, 39-45.
[39]
Hisatomi, Y.; Okumura, K.; Nakamura, K.; Matsumoto, S.; Satoh, A.; Nagano, K.; Yamamoto, T.; Endo, F. Flow cytometric isolation of endodermal progenitors from mouse salivary gland differentiate into hepatic and pancreatic lineages. Hepatology, 2004, 39, 667-675.
[40]
Han, X.D.; Liu, C.; Liu, F.; Xie, Q.H.; Liu, T.L.; Guo, X.Y.; Xu, X.X.; Yang, X.; Zhu, H.; Yang, Z. 64Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. Oncotarget, 2017, 8, 74159-74169.
[41]
Alt, K.; Wiehr, S.; Ehrlichmann, W.; Reischl, G.; Wolf, P.; Pichler, B.J.; Elsässer-Beile, U.; Bühler, P. High-resolution animal PET imaging of prostate cancer xenografts with three different 64Cu-labeled antibodies against native cell-adherent PSMA. Prostate, 2010, 15, 1413-1421.
[42]
Andreozzi, E.M.; Torres, J.B.; Sunassee, K.; Dunn, J.; Walker-Samuel, S.; Szanda, I.; Blower, P.J. Studies of copper trafficking in a mouse model of Alzheimer’s disease by positron emission tomography: comparison of 64Cu acetate and 64CuGTSM. Metallomics, 2017, 15, 1622-1633.
[43]
Ishihara, N.; Matsushiro, T. Biliary and urinary excretion of metals in humans. Arch. Environ. Health, 1986, 41, 324-330.
[44]
Hofman, M.S.; Iravani, A. Gallium-68 prostate-specific membrane antigen PET imaging. PET Clin., 2017, 12, 219-234.
[45]
Gourni, E.; Canovas, C.; Goncalves, V.; Denat, F.; Meyer, P.T.; Maecke, H.R. (R)-NODAGA-PSMA: a versatile precursor for radiometal labeling and nuclear imaging of psma-positive tumors. PLoS One, 2015, 10e0145755
[46]
Haroon, A.; Zanoni, L.; Celli, M.; Zakavi, R.; Beheshti, M.; Langsteger, W.; Fanti, S.; Emberton, M.; Bomanji, J. Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants. Nucl. Med. Commun., 2015, 36, 1065-1075.
[47]
Schillaci, O.; Calabria, F.; Tavolozza, M.; Caracciolo, C.R.; Finazzi-Agrò, E.; Miano, R.; Orlacchio, A.; Danieli, R.; Simonetti, G. Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 589-596.
[48]
Spick, C.; Herrmann, K.; Czernin, J. Evaluation of Prostate Cancer with 11C-Acetate PET/CT. J. Nucl. Med., 2016, 57, 30S-37S.
[49]
Schuster, D.M.; Votaw, J.R.; Nieh, P.T.; Yu, W.; Nye, J.A.; Master, V.; Bowman, F.D.; Issa, M.M.; Goodman, M.M. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J. Nucl. Med., 2007, 8, 56-63.
[50]
Teoh, E.J.; Tsakok, M.T.; Bradley, K.M.; Hyde, K.; Subesinghe, M.; Gleeson, F.V. Recurrent malignant melanoma detected on 18F-fluciclovine PET/CT imaging for prostate cancer. Clin. Nucl. Med., 2017, 42, 803-804.
[51]
Vardhanabhuti, V.; Lo, A.W.; Lee, E.Y.; Law, S.Y. Dual-tacer PET/CT using 18F-FDG and 11C-Acetate in gastric adenocarcinoma with liver metastasis. Clin. Nucl. Med., 2016, 41, 864-865.
[52]
Calabria, F.; D’Auria, S.; Sannino, P.; Schillaci, O. A case of thymoma detected by 18F-choline positron emission tomography/computed tomography. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38, 602.
[53]
Anconina, R. Hod. N.; Levin, D.; Ezroh Kazap, D., Lantsberg, S. incidental detection of metastatic malignant melanoma on 68Ga-prostate-specific membrane antigen PET/CT imaging: Correlative imaging with FDG PET/CT and review of the literature. Clin. Nucl. Med., 2018, 43, 204-206.
[54]
Oh, G.; Miles, K. Subacute cerebellar infarction with uptake on 68Ga-Prostate-specific membrane antigen PET/CT. Clin. Nucl. Med., 2018, 43, 134-135.
[55]
Jochumsen, M.R.; Gormsen, L.C.; Nielsen, G.L. 68Ga-PSMA avid primary adenocarcinoma of the lung with complementary low 18F-FDG uptake. Clin. Nucl. Med., 2018, 43, 117-119.
[56]
Jochumsen, M.R.; Bouchelouche, K. Intense 68Ga-PSMA Uptake in Diverticulum of the Sigmoid Colon. Clin. Nucl. Med., 2018, 43, 110-111.
[57]
Bilgin, R.; Ergül, N.; Çermik, T.F. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand. Nucl. Med. Commun., 2016, 37, 1197-1205.
[58]
Calabria, F. Fifty shades of meningioma: Challenges and perspectives of different PET molecular probes. Clin. Transl. Imaging, 2017, 5, 403-405.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Current Developments in the Detection and Control of Multi Drug Resistance
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Article Metrics
52
2